Treatment of Gastric Metaplasia or Dysplasia by Endoscopic Radiofrequency Ablation: A Pilot Study.

W. Leung, D. Tong, S. Leung, F. S. Chan, T. Tong, R. S. Ho, K. Chu, S. Law
{"title":"Treatment of Gastric Metaplasia or Dysplasia by Endoscopic Radiofrequency Ablation: A Pilot Study.","authors":"W. Leung, D. Tong, S. Leung, F. S. Chan, T. Tong, R. S. Ho, K. Chu, S. Law","doi":"10.5754/HGE14816","DOIUrl":null,"url":null,"abstract":"BACKGROUND/AIMS\nPatients with gastric intestinal metaplasia and dysplasia are at increased risk of gastric cancer development. We tested the feasibility of using endoscopic radiofrequency ablation for the treatment of dysplasia and metaplasia in the stomach.\n\n\nMETHODOLOGY\nPatients who had histologically confirmed low-grade gastric dysplasia or IM were recruited. Endoscopic RFA was performed at 8 week-intervals for a maximum of 3 sessions. All patients were followed up by endoscopy until 12 months post-RFA. The primary outcome was the complete eradication of dysplasia or IM on follow-up. Secondary outcome was adverse events related to RFA.\n\n\nRESULTS\nA total of 12 patients were recruited. Four patients had low-grade dysplasia and the remaining 8 patients had non-dysplastic IM at baseline. At one year after RFA, complete eradication of dysplasia was noted in four patients with low-grade dysplasia (100%). Gastric IM persisted in all patients with baseline metaplasia but the severity of IM improved in 6 (75%) patients. Endoscopic RFA was safe with minimal complications encountered.\n\n\nCONCLUSIONS\nRFA successfully eradicated low-grade dysplasia of the stomach. Gastric IM however persisted after RFA but most patients had evidence of histological improvement on follow up.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 139 1","pages":"748-51"},"PeriodicalIF":0.0000,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5754/HGE14816","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

BACKGROUND/AIMS Patients with gastric intestinal metaplasia and dysplasia are at increased risk of gastric cancer development. We tested the feasibility of using endoscopic radiofrequency ablation for the treatment of dysplasia and metaplasia in the stomach. METHODOLOGY Patients who had histologically confirmed low-grade gastric dysplasia or IM were recruited. Endoscopic RFA was performed at 8 week-intervals for a maximum of 3 sessions. All patients were followed up by endoscopy until 12 months post-RFA. The primary outcome was the complete eradication of dysplasia or IM on follow-up. Secondary outcome was adverse events related to RFA. RESULTS A total of 12 patients were recruited. Four patients had low-grade dysplasia and the remaining 8 patients had non-dysplastic IM at baseline. At one year after RFA, complete eradication of dysplasia was noted in four patients with low-grade dysplasia (100%). Gastric IM persisted in all patients with baseline metaplasia but the severity of IM improved in 6 (75%) patients. Endoscopic RFA was safe with minimal complications encountered. CONCLUSIONS RFA successfully eradicated low-grade dysplasia of the stomach. Gastric IM however persisted after RFA but most patients had evidence of histological improvement on follow up.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
内镜射频消融治疗胃化生或不典型增生:一项初步研究。
背景/ aim胃肠化生和不典型增生患者发生胃癌的风险增加。我们测试了使用内镜射频消融治疗胃发育不良和化生的可行性。方法招募组织学证实为轻度胃发育不良或IM的患者。内镜下射频消融术每8周进行一次,最多3次。所有患者均接受内镜随访,直至rfa后12个月。在随访中,主要结果是完全根除不典型增生或IM。次要终点是与RFA相关的不良事件。结果共纳入12例患者。4例患者为低度发育不良,其余8例患者基线时为非发育不良IM。RFA后1年,4例低级别发育不良患者(100%)完全根除了发育不良。所有基线化生患者的胃IM持续存在,但6例(75%)患者IM的严重程度有所改善。内镜下射频消融术是安全的,并发症很少。结论srfa可成功根治胃低度发育不良。然而,胃IM在RFA后持续存在,但大多数患者在随访中有组织学改善的证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Hepato-gastroenterology
Hepato-gastroenterology 医学-外科
自引率
0.00%
发文量
1
审稿时长
1.9 months
期刊介绍: Hepato-Gastroenterology has been discontinued as of 2015. Extremely limited quantities of back issues in print available for sale.
期刊最新文献
Scheepswrak Oude Inschot, Hoppa III Hepatocellular carcinoma. Esophageal carcinoma. The Rule of Law, Economic Efficiency and Social Justice: A Primer for the President Predicting hepatocellular carcinoma recurrence and survival
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1